Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026773 | 1.00 | PAOX (0.52) | PAOXKDM4CKDM4APHF8KDM2A | |
| SCHEMBL20411505 | 1.00 | PAOX (0.52) | PAOXKDM4CKDM4APHF8KDM2A | |
| SCHEMBL8896028 | 1.00 | PAOX (0.52) | PAOXKDM4CKDM4APHF8KDM2A | |
| SCHEMBL1783020 | 1.00 | PAOX (0.52) | PAOXKDM4CKDM4APHF8KDM2A | |
| SCHEMBL18314426 | 1.00 | PAOX (0.52) | PAOXKDM4CKDM4APHF8KDM2A | |
| SCHEMBL12526756 | 1.00 | PAOX (0.52) | PAOXKDM4CKDM4APHF8KDM2A | |
| SCHEMBL16431234 | 1.00 | PAOX (0.52) | PAOXKDM4CKDM4APHF8KDM2A | |
| SCHEMBL290187 | 0.97 | PAOX (0.48) | PAOXKDM4CKDM4APHF8KDM2A | |
| SCHEMBL130602 | 0.90 | — | — | |
| SCHEMBL7542023 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117904435-A | Solvent extraction system for separating zirconium and hafnium, preparation method thereof and separation method of zirconium and hafnium | 北京科技大学 | 2024-04-19 | — | — | CN | claimed |
| CN-102826977-A | Synthesis method and application of 7-methoxy-3,7-dimethyloctyl aldehyde | TIANNING FLAVOR & FRAGRANCE JIANGSU CO LTD | 2012-12-19 | — | — | CN | claimed |
| CN-119552065-A | Method for preparing multi-carbon methyl ketone from acetone | 万华化学集团股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12222653-B2 | Method for forming semiconductor structure | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2025-02-11 | — | — | US | disclosed |
| US-20250000088-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-01-02 | — | — | US | disclosed |
| EP-4424164-A1 | ANT CONTROL AGENT AND ANT CONTROL METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-09-04 | — | — | EP | disclosed |
| CN-117904435-A | Solvent extraction system for separating zirconium and hafnium, preparation method thereof and separation method of zirconium and hafnium | 北京科技大学 | 2024-04-19 | — | — | CN | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024004872-A1 | PROCESSING METHOD FOR SILICON CARBIDE SINGLE CRYSTAL SUBSTRATE, SILICON CARBIDE SINGLE CRYSTAL SUBSTRATE PROCESSING SYSTEM, AND REPLENISHING LIQUID | 東京応化工業株式会社 | 2024-01-04 | — | — | WO | disclosed |
| WO-2024004864-A1 | SILICON CARBIDE SINGLE CRYSTAL SUBSTRATE PROCESSING METHOD, AND SILICON CARBIDE SINGLE CRYSTAL SUBSTRATE PROCESSING SYSTEM | 東京応化工業株式会社 | 2024-01-04 | — | — | WO | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20070281308-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION | TRILINK BIOTECHNOLOGIES, LLC | 2007-12-06 | — | — | US | disclosed |
| US-7186782-B2 | Hydrogenation catalyst composition and process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2007-03-06 | — | — | US | disclosed |
| US-20060041079-A1 | Hydrogenation catalyst composition and process for hydrogenation of conjugated diene polymer | TSRC CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6881797-B2 | Process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2005-04-19 | — | — | US | disclosed |
| US-20040082727-A1 | Process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (CN) | 2004-04-29 | — | — | US | disclosed |
| EP-0745605-B1 | Liquid methyltin halide compositions | ATOFINA CHEM INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-5853799-A | Liquid methyltin halide compositions | ATOFINA CHEMICALS, INC., A CORP. OF PENNSYLVANIA | 1998-12-29 | — | — | US | disclosed |
| US-5725904-A | Liquid methyltin halide compositions | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0745605-A2 | Liquid methyltin halide compositions | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1996-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281308-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION | POLRMT, POLI, POLM | PAOX 156/4885KDM4C 3382/4885KDM4A 2623/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | PAOX 1955/4885KDM4C 4293/4885KDM4A 4430/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | PAOX 1955/4885KDM4C 4293/4885KDM4A 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.